Insulet Corporation

Stage 4 · Declining · week 8

As of Oct 22, 2026, Insulet is in Stage 4, the downtrend phase, now in week 8 (since Aug 27, 2026). It closed at $148.12, 57.2% below its 52-week high and below its 200-day average, which is falling.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. More about the company

$148.12

+4.38% today

$10.3B · Large cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PODD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 16w

S2 40w

S4 28w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 16w → S1 12w → S4 13w → S1 2w → S2 40w → S3 8w → S2 11w → S3 3w → S2 10w → S3 9w → S4 28w → S1 3w → S4 8w current

Total tracked: 165 weeks across 13 stage runs.

PODD among Medical Devices94th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…94	PODDInsulet Corporation	Stage 4 · wk 8	21	+8.5%

vs 52W High

-57.2%

$130.47 lo$346.36 hi

57.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 8

1w13w26w

Week 8, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-19.0%

200 DMA: $182.91 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.74x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↗

Short-term trend rising gently

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+8.5%

-9.3%

-22.9%

YTD

-47.6%

-55.0%

Scan Membership

Breakout Watch

Latest: 2025-09-02

13 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 8 · Vol 0.74x

2026-10-21S4

Wk 8 · Vol 0.40x

2026-10-20S4

Wk 8 · Vol 0.68x

2026-10-19S4

Wk 8 · Vol 1.40x

2026-10-16S4

Wk 8 · Vol 0.96x

2026-10-15S4

Wk 7 · Vol 0.93x

2026-10-14S4

Wk 7 · Vol 1.30x

2026-10-13S4

Wk 7 · Vol 0.76x

2026-10-12S4

Wk 7 · Vol 0.75x

2026-10-09S4

Wk 7 · Vol 0.48x

2026-10-08S4

Wk 6 · Vol 0.88x

2026-10-07S4

Wk 6 · Vol 0.58x

Moving averages & range

50 DMA

$140.45

200 DMA

$182.91

52W High

$346.36

52W Low

$130.47

5D Low

$141.10

Resistance levels (recent highs)

20d High

$148.12

60d High

$169.70

120d High

$171.39

250d High

$346.36

Next resistance

+14.6%

to 60d High

P/E (TTM)

27.7

Forward 19.2

Earnings Growth (YoY)

+328.6%

Revenue +23.5%

ROE

+26.0%

Profit margin +12.3%

Dividend Yield

0.00%

P/B 7.2

Insulet: quick answers

What stage is Insulet in?

As of Oct 22, 2026, Insulet (PODD) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 27, 2026 and is in week 8. What the four stages mean

Is Insulet in an uptrend?

No. Insulet is in a Stage 4 downtrend. It trades 19.0% below its 200-day average, which is falling.

How far is Insulet from its 52-week high?

Insulet closed at $148.12 on Oct 22, 2026, 57.2% below its 52-week high of $346.36. Its 52-week low is $130.47.

How has Insulet performed over the past year?

As of Oct 22, 2026, Insulet is down 55.0% over the past year and down 47.6% so far in 2026.

Which sector and industry is Insulet in?

Insulet is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.